ABSTRACT
Introduction Indoor residual spraying (IRS) and insecticide-treated bed-nets (ITNs) are cornerstone malaria prevention methods in Madagascar. This retrospective observational study uses routine data to evaluate the impacts of IRS overall, sustained IRS exposure over multiple years, and level of spray coverage (structures sprayed/found) in nine districts where non-pyrethroid IRS was deployed to complement standard pyrethroid ITNs from 2017 to 2020.
Methods Multilevel negative-binomial generalized linear models were fit to estimate the effects of IRS exposure overall; consecutive years of IRS exposure; and spray coverage level on monthly all-ages population-adjusted malaria cases confirmed by rapid diagnostic test at the health facility level. The study period extended from July 2016 to June 2017. Facilities missing data and non-geolocated communes were excluded. Facilities in IRS districts were matched with control facilities by propensity score analysis. Models controlled for ITN survivorship, mass drug administration coverage, precipitation, enhanced vegetation index, seasonal effects, and district. Predicted cases under a counterfactual no IRS scenario and number of cases averted by IRS were estimated using the fitted models.
Results Exposure to IRS overall reduced case incidence by an estimated 30.3% from 165.8 cases per 1,000 population (95%CI=139.7-196.7) under a counterfactual no IRS scenario, to 114.3 (95%CI=96.5-135.3), over 12 months post-IRS campaign in 9 districts. A third year of IRS reduced malaria cases 30.9% more than a first year (IRR=0.578, 95%CI=0.578-0.825, P<0.001) and 26.7% more than a second year (IRR=0.733, 95%CI=0.611-0.878, P=0.001). There was no significant difference between a first and second year (P>0.05). Coverage of 86%-90% was associated with a 19.7% reduction in incidence (IRR=0.803, 95%CI=0.690-0.934, P=0.005) compared to coverage ≤85%, although these results were not robust to sensitivity analysis.
Conclusion This study demonstrates that non-pyrethroid IRS appears to substantially reduce malaria incidence in Madagascar and that sustained implementation of IRS over 3 years confers additional benefits.
What is already known on this topic The use of non-pyrethroid insecticides for indoor residual spraying (IRS) in communities using pyrethroid-based insecticide treated nets (ITNs) is associated with reduced malaria prevalence, and with reduced malaria incidence in some settings.[1] To date, few studies have investigated the impact of high spray coverage and sustained IRS implementation over multiple years.[2,3]
What this study adds This study estimates the impact of IRS in a setting with heterogenous malaria transmission and variation in intervention impact at the subnational level. Additionally, this study presents evidence of a benefit to continuing IRS implementation over multiple consecutive years.
How this study might affect research, practice, or policy The results reported here bolster the evidence around the effectiveness of non-pyrethroid insecticides for IRS while suggesting that policymakers should consider the benefits of sustaining IRS implementation over multiple years when undertaking decisions to move locations and/or withdraw IRS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the PMI VectorLink Project (USAID/PMI contract AID-OAA-1-17-00008, task order AID-OAA-TO-17-00027).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are available from the authors upon reasonable request.
